Survival in β-thalassaemia major in the UK: Data from the UK thalassaesnia register

Lancet

Volumn 355, Issue 9220, 2000, Pages 2051-2052

  Modell, B ^a   Khan, M ^a   Darlison, M ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON CHELATING AGENT;

ADOLESCENT; ADULT; BETA THALASSEMIA; CHILDHOOD MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NOTE; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME;

EID: 0034631379     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02357-6     Document Type: Article

References (5)

1. B Modell V Berdoukas The clinical approach to thalassaemia 1984 Grune and Stratton New York and London
2. B Modell E Letsky D Flynn R Peto DJ Weatherall Survival and desferrioxamine in thalassaemia major BMJ 284 1982 1081 1084
3. A Piga, F Longo, A Consolati, A De Leo, L Carmellino, Mortality and morbidity in thalassaemia with conventional treatment. In: Bone marrow transplant 19 (supple 2), proceedings of the third international conference on bone marrow transplantation in thalassaemia. 1997: 11–13
4. AV Hoffbrand B Wonke Iron chelation therapy J Intern Med 242 suppl 740 1997 S17 S41
5. B Wonke C Wright AV Hoffbrand Combined therapy with deferiprone and desferrioxamine Br J Haematol 103 1998 361 364